智通财经网·2026-02-09 13:23Core Viewpoint - Novo Nordisk (NVO.US) is suing Hims & Hers (HIMS.US) for allegedly producing counterfeit versions of its weight loss drug, Wegovy, and has accused Hims of patent infringement regarding the active ingredient semaglutide [1][2]. Group 1: Legal Actions and Allegations - Novo Nordisk claims that Hims has infringed its semaglutide patent in the U.S., which is the active ingredient in its blockbuster drugs Ozempic and Wegovy [1]. - The lawsuit was filed in Delaware, with Novo Nordisk seeking damages including "reasonable royalties" and lost profits due to Hims' actions [2]. - Hims had previously announced a compound weight loss drug, prompting strong reactions from Novo Nordisk and regulatory bodies, leading Hims to abandon its plans to sell the counterfeit version [1][2]. Group 2: Company Responses and Market Impact - Novo Nordisk's legal counsel expressed outrage over Hims' decision to launch a counterfeit product, marking a significant turning point in their relationship [1]. - Following the announcement of the lawsuit, Hims' stock price fell by 21%, while Novo Nordisk's shares rose nearly 6% [3]. - The FDA has committed to taking action against counterfeit weight loss drugs, and Hims has been referred to the Department of Justice for potential federal law violations [3].